All News
Outcomes Switching to Monotherapy: SEAM-RA Trial
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
Read Article
The use of telephone consultations as an additive tool in the outpatient care of patients with rheumatic disease showed good acceptance. Further work to study implementation of telephone and/or video consultations in clinics @RheumNow #ACR20 Abstr#0599
Dr. Antoni Chan synovialjoints ( View Tweet)
Pearls from @anisha_dua for differentiating atherosclerosis vs. vasculitis inflammation on imaging:
1. Look at the Axillary arteries - they tend to be less likely affected by atherosclerosis
2. Vasculitic lesions tend to be concentric & longer/continuous
#ACR20 #RheumTwitter
Adam Kilian MD KilianMD ( View Tweet)
Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD
Jilaine Bolek Berquist BolekBerqui ( View Tweet)
@AngusWorthing @r_burmester Is the ‘thieves’ market’ session named after our history of stealing drugs? 😱 😂
Puja Mehta 🧩 DrPujaMehta1 ( View Tweet)
Today's #ACR20 lecture @r_burmester shows the biologic revolution was a result of serendipity -- this will spark the long-awaited new & improved name of our profession: serendipitology! Hi I'm Dr. Worthing I'm a Serendipitologist. I use drugs intended for infections, cancer etc.! https://t.co/buDqwAVK9u
Angus Worthing MD AngusWorthing ( View Tweet)
Dr Joan Merrill presents a phase 2 trial
use of Iberdomide in patients with #SLE
-Novel MOA —> blocks TF Ailos and Ikaros
Conclusion
-Primary end point was met at week 24
-Effects greater in Aiolos high/Type 2 IFN high
-Iverdomdie was tolerated well
#Lupus
#ACR20
#ACRambassador https://t.co/zpQR9ceV7p
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
We need to start utilizing and normalizing anti phosphatidylserine/prothrombin antibody ordering in clinical practice #ACR20 https://t.co/LeeHnuX9x0
Emily Littlejohn ELittlejohnDO ( View Tweet)
Nice succinct review of recent DOAC studies in #APS by Dr. Ortel. Recommends avoiding DOACs in triple positive pts #antiphospholipid #ACR20 https://t.co/Hc6ye3mvTg
E. Sloan esloanmd ( View Tweet)
Editors Pick for #ACR20—Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial https://t.co/cunDxVl5XG https://t.co/OGItXCuWDI
Links:
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis
-Compared to rituximab, has more B-cell depletion in tissue and #SLE patients
-Meaningful benefits over SOC alone on renal response through week 104.
-Phase 3 REGENCY pending.
#ACR20
#ACRambassador
#Rheumatology https://t.co/aPi1yueAiV
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
Rheumatoid arthritis and lung disease in the spotlight at #ACR20 by @jeffsparks
https://t.co/0Dth0k6uve https://t.co/pGfGtq8Sz7
Links:
Dr. John Cush RheumNow ( View Tweet)
After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
Thanks @EBRheum for a great rundown of how to keep up with the #rheumatology literature- particularly liked the reminder to use tech & @Twitter as well as reading.
"#RheumTwitter is fun, it's collaborative, it's full of doughnuts."
Proud to be a rheum trainee!😄
#ACR20 @RheumNow https://t.co/V1zaUD1KCJ
Mrinalini Dey DrMiniDey ( View Tweet)
Should ARBs be adjunct Rx in GCA?
Plausible target:
- previous pharmacoepi
- ATII expressed in GCA inflamm lesions
- ATII induced pro-inflamm in PBMC/co-cultured VSMC
- steroids modulate ATII expression in GCA TA ex vivo
Maybe worth testing?
Cid et al #ACR20 ABST0510 @RheumNow https://t.co/mNNzZVYe7g
David Liew drdavidliew ( View Tweet)
@RheumNow #acr20 abs0622 infection induced MPO anca vasc: most common triggers viruses(35.2%), mycobacterial (29.4%)& bacterial inf (29.4%). Onset 3 mo post inf. (70.5%) renal involvement, w/ biopsy-proven GN in 53%. 17.6%died. Rx steroids+abx, CYC in 47%.
Olga Petryna DrPetryna ( View Tweet)
We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients.
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow
https://t.co/1SsL9qLJD3
k dao KDAO2011 ( View Tweet)
Is diet important in gout control? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Robert B Chao, MD doctorRBC ( View Tweet)
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
Olga Petryna DrPetryna ( View Tweet)